Abstract
As the third generation platinum antitumor drug with independent intellectual property rights,a number of basic and clinical research shows lobaplatin can effectively inhibit the proliferation of human breast cancer cell lines including triple-negative breast cancer in vivo. Compared with the cisplatin-based regimens, lobaplatin-based regimens have similar efficacy, and better safety profde.It becomes the new treatment option of metastatic breast cancer, and remains to he further study to optimize clinical rational drug use.
| Original language | English |
|---|---|
| Pages (from-to) | 646-648 |
| Number of pages | 3 |
| Journal | Cancer Research and Clinic |
| Volume | 25 |
| Issue number | 9 |
| DOIs | |
| State | Published - 28 Sep 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical research
- Lobaplatin
- Metastatic breast cancer
- Pharmacodynamics
Fingerprint
Dive into the research topics of 'Research progress of new anticancer drug lobaplatin in treatment of metastatic breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver